Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# NeuroPerspective

NI Research: Neuro Publications and Consulting

## Sitemaps

- [XML Sitemap](https://www.niresearch.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [NeuroPerspective Reviews Psychedelics, Huntington's, and Migraine](https://www.niresearch.com/neuroperspective-reviews-psychedelics-huntingtons-and-migraine/) - In a most remarkably accelerated process, the Psychedelics, which constitute a novel and heterogeneous class of therapeutic candidates, are soon to take their revolutionary leap from investigational to commercial, as Compass’ COMP360/psilocybin appears likely to receive FDA approval during 4Q, setting the stage for a nearterm first launch of a classical psychedelic, this for
- [NeuroPerspective Reviews PTSD, Autism, Epilepsy](https://www.niresearch.com/neuroperspective-reviews-ptsd-autism-epilepsy/) - NeuroPerspective has released its Spring 2026 issue, featuring our reviews of PTSD, an area with expanding therapeutic possibilities: Autism, a fast- growing CNS disorder; and Epilepsy, where there have been several encouraging datasets in recent months. Our review of PTSD recognizes trauma as a human growth industry: In theory, many traumatizing factors could be
- [NeuroPerspective Reviews 2025, Previews 2026](https://www.niresearch.com/neuroperspective-reviews-2025-previews-2026/) - NeuroPerspective has released its Winter 2026 issue, featuring our annual look back at the preceding year, and our Preview of the year ahead. 2025 was a highly productive year for several subsectors of the neurotherapeutics space, including Psychedelics, Epilepsy, Narcolepsy, and muscarinics. The Psychedelic area has matured faster than we ever could have anticipated, both NeuroPerspective has released its Winter 2026 issue, featuring our annual look back at the preceding year, and our Preview of the year ahead. 2025 was a highly productive year for several subsectors of the neurotherapeutics space, including Psychedelics, Epilepsy, Narcolepsy, and muscarinics. The Psychedelic area has matured faster than we ever could have anticipated, both
- [NeuroPerspective Reviews Alzheimer's, Depression, Narcolepsy](https://www.niresearch.com/neuroperspective-reviews-alzheimers-depression-narcolepsy/) - NeuroPerspective has released its Fall 2025 issue, featuring our annual comprehensive review of Alzheimer’s, as well as reviews of Depression and Narcolepsy. Our Alzheimer’s review appraises the impact of the commercial advents of Eisai/Biogen’s Leqembi/lecanemab and Lilly’s Kisunla/donanemab. They provide an imperceptible slowing of disease progression and a rare but not inconsequential risk of ARIA, that
- [NeuroPerspective Reviews Psychedelics, Parkinson's, Stroke](https://www.niresearch.com/neuroperspective-reviews-psychedelics-parkinsons-stroke/) - Psychedelics constitute a novel and heterogeneous class of therapeutic candidates that is starting to take shape via clinical data. Just in the past few days, critical and successful clinical readouts have been announced by Compass Pathways and Atai Beckley, recently Gilgamesh and Transcend had positive clinical results. Cybin has data coming soon. Lykos Therapeutics, whose
- [NeuroPerspective Reviews Schizophrenia, ALS, Addiction](https://www.niresearch.com/neuroperspective-reviews-schizophrenia-als-addiction/) - NeuroPerspective has released its Spring 2025 issue, featuring comprehensive reviews of neurotherapeutics programs addressing Schizophrenia, ALS, and Addiction. The Schizophrenia area is on the verge of its most significant transformation in decades, as the pharma industry is seeing a heated competition between companies attempting to ride the new wave of novel and refined mechanisms aimed at
- [NeuroPerspective Releases 2024/2025 Review/Preview](https://www.niresearch.com/neuroperspective-releases-2024-2025-review-preview/) - NeuroPerspective has released its Winter 2025 issue, featuring our comprehensive Review of 2024 and Preview of 2025 for the neurotherapeutics area. In terms of 2024, the availabilities of Eisai/Biogen’s Leqembi and Lilly’s Kisunla constitute a dress rehearsal, for the eventual availability of genuinely impactful disease-modifiers for Alzheimer’s. The risks are more easily quantified than their benefit, which we
- [NeuroPerspective Reviews AD, Anxiety, TBI](https://www.niresearch.com/neuroperspective-reviews-ad-anxiety-tbi/) - NeuroPerspective has released its Fall 2024 issue, featuring our annual comprehensive review of Alzheimer’s, as well as of Anxiety and TBI. Our Alzheimer's review appraises the current, minuscule impact of the commercial advents of Eisai/Biogen’s lecanemab and Lilly’s donanemab. They are more similar than different, providing barely (if that) perceptible slowing of disease progression and a rare but
- [NeuroPerspective Reviews Psychedelics, Epilepsy, FTD](https://www.niresearch.com/neuroperspective-reviews-psychedelics-epilepsy-ftd/) - The Summer 2024 issue of NeuroPerspective has been released. It features three comprehensive therapeutic area reviews: Psychedelics, Epilepsy, and Frontotemporal Dementia. 1) There is no area of neurotherapeutics that combines promise and controversy in the same measure as Psychedelics, a novel class undergoing rapid developmental transformation. Recently, the most salient drama has involved the utilization
- [NeuroPerspective Reviews Depression, PTSD, and Stroke](https://www.niresearch.com/neuroperspective-reviews-depression-ptsd-and-stroke/) - The Spring 2024 issue of NeuroPerspective features three comprehensive therapeutic area reviews. First is Depression, an area on the cusp of being transformed as Psychiatry adds new therapeutic tools, and begins to meaningfully parse large patient populations based on phenotypic or biomarker differentiators. New mechanisms are in clinical stage, ranging from the kappa opioid antagonists from JNJ and Neumora; to
- [NP Reviews 2023, Previews 2024](https://www.niresearch.com/np-reviews-2023-previews-2024/) - NeuroPerspective has released its Winter 2024 issue, featuring our comprehensive Review of 2023 and Preview of 2024 for the neurotherapeutics area. While some will consider the launch of Eisai/Biogen’s Leqembi to have been the premier event for 2023, we consider this a first step, a dress rehearsal, for the eventual availability of genuinely impactful disease-modifiers
- [NeuroPerspective Reviews Alzheimer’s, Huntington’s, and ADHD](https://www.niresearch.com/neuroperspective-reviews-alzheimers-huntingtons-and-adhd/) - NeuroPerspective has released its Fall 2023 issue, featuring our annual comprehensive reviews of Alzheimer’s, as well as Huntington’s and ADHD. The Fall 2023 issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer's space, including an appraisal of the impact that can be expected from the Leqembi launch, which may mean more to the psychology of
- [NeuroPerspective Reviews Psychedelics, Parkinsons, MS](https://www.niresearch.com/neuroperspective-reviews-psychedelics-parkinsons-ms/) - NeuroPerspective has released its Summer 2023 issue, featuring comprehensive reviews of the Psychedelic Therapeutics area, as well as neurotherapeutics programs addressing Parkinson's and Multiple Sclerosis. There is no area in neurotherapeutics that is in such frequent and potentially substantive transformation as Psychedelics. Along with Alzheimer's, it has become one of the two areas to which NP
- [NP Reviews Schizophrenia, ALS, Addiction](https://www.niresearch.com/np-reviews-schizophrenia-als-addiction/) - NeuroPerspective has released its Spring 2023 issue, featuring comprehensive reviews of neurotherapeutics programs addressing Schizophrenia, ALS, and Addiction. The Schizophrenia area had been relatively moribund since the field became dominated by Second Generation (‘atypical’) antipsychotics, but that is now changing, as novel mechanisms aimed at the three domains of schizophreniform illness are maturing. The most tangible
- [NeuroLicensing 2023](https://www.niresearch.com/neurolicensing-2023/) - NeuroLicensing 2023 has been released. It is completely revised and updated, featuring: Analysis of current trends in CNS deal activity and parametersCandid assessments of the major and midsize companies involved in CNS inlicensing: Who is seeking assets in which therapeutic areas, and their exclusions; Which companies are the strongest inlicensing candidates in specific areas. Corporate licensing agendas
- [NeuroPerspective Overviews CNS 2022/23](https://www.niresearch.com/neuroperspective-overviews-cns-2022-23/) - The Winter issue of NeuroPerspective has been released. This is the Overview Issue, which assesses the past year, with a particular eye to how the Alzheimer’s landscape has (and hasn’t evolved), and looks ahead to forecast key developments that can be expected in 2023. 2023 begins a two to three year sequence of trial completions that will
- [NeuroPerspective Reviews Alzheimer's, Anxiety, TBI](https://www.niresearch.com/neuroperspective-reviews-alzheimers-anxiety-tbi/) - The Fall 2022 issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer's space, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets. One major theme is the resuscitation of the amyloid antibody space by the FDA, initially led by Biogen's Aduhelm, which was derailed by discord around data
- [NeuroPerspective on Psychedelics, Epilepsy, Rett](https://www.niresearch.com/neuroperspective-on-psychedelics-epilepsy-rett/) - The Summer issue of NP has been released, evaluating the areas of Psychedelic Therapeutics, Epilepsy, and Rett Syndrome. 1)Psychedelic Therapeutics were the sole focus of the March/April 2021 edition of NP, but no area has been evolving more rapidly, or received more media coverage, the latter imbued with varying degrees of superheated hype. This return
- [NeuroPerspective Reviews Depression, PTSD, Stroke](https://www.niresearch.com/neuroperspective-reviews-depression-ptsd-stroke/) - The Spring 2022 issue of NeuroPerspective has been released, featuring in-depth reviews of Depression, PTSD and Stroke. Depression continues to be a frustratingly incomplete success for psychopharmacology. The majority of patients do not find adequate relief from their first trial, and 25% do not find sufficient benefit from any of the antidepressants they try. Aversive
- [NeuroPerspective Reviews/Previews 2021/2022](https://www.niresearch.com/neuroperspective-reviews-previews-2021-2022/) - The Winter (January/February/March) 2022 issue of NeuroPerspective has been released. It provides a comprehensive review of 2021, a year that provided very little in the way of respite, though funding by institutional investors and partners came in third all-time, behind 2018 and the remarkable 2020. Partnering upfront payments were off 38% from 2020, institutionalization investment
- [Parkinson's/ALS Reviewed by NeuroPerspective](https://www.niresearch.com/parkinsons-als-reviewed-by-neuroperspective-2/) - NI Research has released the November/December 2021 issue of NeuroPerspective, which features comprehensive reviews for two major neurodegenerative disorders: Parkinson’s and ALS. These reviews include a consideration of the current thinking around pathophysiology and therapeutic targets, including the protein aggregates considered to be associated with these disorders: Alpha-synuclein, TDP-43, SOD1, and c9orf72. Neuroinflammation, GBA as
- [Alzheimer's and Huntington's Reviewed](https://www.niresearch.com/alzheimers-and-huntingtons-reviewed/) - The September/October issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer's space, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets. One major theme is the resuscitation of the amyloid antibody space by the FDA, led by Biogen's Aduhelm. But Biogen, due partly to their gross misreading of
- [Midyear Overview and Addiction](https://www.niresearch.com/midyear-overview-and-addiction/) - The July/August 2021 issue of NeuroPerspective begins with the Mid-Year Overview of the neurotherapeutics sector. It includes extensive coverage of and commentary about the FDA's dramatically negligent approval of Biogen's Aduhelm/aducanumab, negligent because of its disregard for its own ADCOM recommendations, omission of even basic limitations on labeling and REMS requirements. Other news coverage includes the mixed
- [NP on Schizophrenia and MS](https://www.niresearch.com/np-on-schizophrenia-and-ms/) - NeuroPerspective has released its May/June 2021 issue, featuring comprehensive reviews of neurotherapeutics programs addressing Schizophrenia and Multiple Sclerosis. The Schizophrenia area has been relatively static since the field became dominated by Second Generation (‘atypical’) antipsychotics. Efforts to widen the range of symptoms effectively treated to include cognitive and negative symptoms have generally fallen short. But there
- [NeuroPerspective on Psychedelics](https://www.niresearch.com/neuroperspective-on-psychedelics/) - NeuroPerspective has released its March/April 2021 issue, featuring its first-ever, comprehensive review of the rapidly-expanding Psychedelic Therapeutics space, where substances formerly relegated to sacramental and/or illegal status are being formally tested as treatments for CNS disorders. Psilocybin, LSD, DMT, 5-MeO-DMT are some of the ‘classic’ psychedelic substances being explored, along with ‘empathogens’ like MDMA, dissociative drugs like ketamine,
- [NeuroLicensing 2021 Released](https://www.niresearch.com/neurolicensing-2021-released/) - NI Research is pleased to announce the release of NeuroLicensing 2021The indispensable guide to: Current trends in deal parametersPharma track records in CNS licensingWhat each company is looking for in terms of therapeutic areas and stages of development NIR’s candid evaluations of pharma performance and capabilities NeuroLicensing 2021 is a vital and affordable resource for licensing teams on both sides
- [NeuroPerspective Reviews/Previews 2020/2021](https://www.niresearch.com/neuroperspective-reviews-previews-2020-2021/) - The January/February 2021 issue of NeuroPerspective has been released. It provides a comprehensive review of 2020, a year that was horrific in the global sense, but surprisingly positive within the neurotherapeutics category; and a candid appraisal of what to anticipate in 2021, a year that will have a number of high-interest datasets coming, but is
- [NeuroPerspective Reviews Autism](https://www.niresearch.com/neuroperspective-reviews-autism/) - The November/December 2020 issue of NeuroPerspective reviews Autism Spectrum Disorder. The nomenclature itself is a confession of conceptual sloppiness; ASD is a vaguely defined umbrella category, under which huddles a highly heterogeneous assortment of phenotypic presentations, divergent in their type, intensity, and prognosis. ASD is always impactful, and it can be devastating on several levels,
- [Alzheimer's and FTD Reviewed](https://www.niresearch.com/alzheimers-and-ftd-reviewed/) - The September/October issue of NeuroPerspective has been released. It features our comprehensive annual review of the Alzheimer's space, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets. Aducanumab has somehow survived at the head of the regulatory menu, its prospects are discussed at length. Despite the early disappointments in PSP, tau therapeutics are now
- [Midyear Review and TBI](https://www.niresearch.com/midyear-review-and-tbi/) - The July/August 2020 issue overviews developments in the neuro sector YTD, including a number of partnerships, including the Takeda/Neurocrine alliance; a robust funding environment for small companies, including Athira, Prilenia, Engrail, Autobahn, QurAlis, Atara,and Aspen Neuroscience. Capsule summaries for 80+ companies are included, plus commentary regarding trends in investment and partnership dynamics. TBI is reviewed
- [Depression/PTSD Reviewed](https://www.niresearch.com/depression-ptsd-reviewed/) - The May/June 2020 issue of NeuroPerspective has been released, featuring in-depth reviews of Depression and PTSD. Depression represents a glaringly incomplete success for psychopharmacology. The majority of patients do not find adequate relief from their first trial, and 25% do not find sufficient benefit from any of the antidepressants they try. Aversive side effects, including weight gain and
- [Huntington's and Epilepsy Reviewed](https://www.niresearch.com/huntingtons-and-epilepsy-reviewed/) - NI Research has released the March/April 2020 issue of NeuroPerspective, which features comprehensive reviews for Huntington's and Epilepsy. The HD review includes an appraisal of the current thinking around pathophysiology and therapeutic targets, including the varying approaches to modifying the production of mutant huntington, considered the core pathology of this monogenic neurodegenerative disorder. Isoform selective
- [NeuroPerspective's Review/Preview for 2020 Released](https://www.niresearch.com/neuroperspectives-review-preview-for-2020-released/) - The January/February 2020 issue of NeuroPerspective has been released. It provides a comprehensive review of 2019, and a candid appraisal of what to anticipate in 2020. 115 companies have capsule summaries of current activities and coming events, including AbbVie, Acorda, Adamas, Alkahest, Alkermes, Aptinyx, ATAI Life Sciences, Axon-Neuroscience, Axsome, Biogen, Biohaven, Blackthorn, Centrexion, Cognition Therapeutics, Denali,
- [Parkinson's/ALS Reviewed By NeuroPerspective](https://www.niresearch.com/parkinsons-als-reviewed-by-neuroperspective/) - NI Research has released the November/December issue of NeuroPerspective, which features comprehensive reviews for two major neurodegenerative disorders: Parkinson’s and ALS. These reviews include a consideration of the current thinking around pathophysiology and therapeutic targets, including the protein aggregates considered to be associated with these disorders: Alpha-synuclein, TDP-43, and c9orf72. Neuroinflammation, GBA as a target,
- [Alzheimer's/FTD Reviewed for 2019](https://www.niresearch.com/alzheimers-ftd-reviewed-for-2019/) - The September/October 2019 issue of NeuroPerspective features our comprehensive annual review of the Alzheimer's space, including a review of the current conceptual trends vis-a-vis pathophysiology, mechanisms, and therapeutic targets. 2019 has seen greatly expanded efforts aimed at harnessing neuroimmunological components in the service of avoiding toxic levels of inflammation, while promoting microglial clearance of aberrant
- [MidYear 2019 Review and Migraine](https://www.niresearch.com/midyear-2019-review-and-migraine/) - The July/August 2019 issue overviews developments in the neuro sector YTD, including coverage of paradigm shifts in the treatment of depression, SMA, and migraine. Capsule summaries for 80+ companies are included, plus commentary regarding trends in investment and partnership dynamics. Migraine is reviewed in full for the first time in four years, with an assessment
- [MS and Insomnia Reviewed by NeuroPerspective](https://www.niresearch.com/807-2/) - The May/June 2019 issue of NeuroPerspective has been released, offering detailed reviews of two therapeutic areas, as well as coverage and commentary regarding significant developments in the CNS therapeutics space. The first therapeutic sector review covers Multiple Sclerosis, which to some degree represents the kind of therapeutic efficacy and choices that the rest of the neurotherapeutics area
- [NeuroPerspective Reviews Schizophrenia and Stroke](https://www.niresearch.com/neuroperspective-reviews-schizophrenia-and-stroke/) - The March/April 2019 issue of NeuroPerspective has been released, offering detailed reviews of two therapeutic areas, as well as coverage and commentary regarding significant developments in the CNS therapeutics space. The first therapeutic sector review covers Schizophrenia, the most devastating of all the psychiatric disorders, one which comprises the awkward melding of multiple schizophreniform phenotypes with very
- [NeuroPerspective Releases Review/Preview of 2018/19](https://www.niresearch.com/neuroperspective-releases-review-preview-of-2018-19/) - The January/February issue of NeuroPerspective has been released. It provides a comprehensive review of 2018, and a full appraisal of what to anticipate in 2019. 130 companies have capsule summaries of current activities and coming events, including AbbVie, Acorda, Adamas, Alkahest, Alkermes, Allergan, Biogen, Biohaven, Blackthorn, Denali, JNJ, Lilly, Lundbeck, Lysosomal Therapeutics, Marinus, Minerva, Neurocrine Biosciences,
- [Pain Reviewed By NeuroPerspective](https://www.niresearch.com/pain-reviewed-by-neuroperspective/) - The November/December issue of NeuroPerspective features a comprehensive review of the Pain space, divided into two major sub-sections, Nociceptive (including Inflammatory) Pain and Neuropathic Pain. Even as attention has necessarily been focused upon the Opioid Epidemic that had its roots in an overreliance upon prescription opioid analgesics, the Pain field has yet to develop non-opioid
- [Alzheimer's/FTD Reviewed](https://www.niresearch.com/alzheimers-ftd-reviewed/) - The September/October issue of NeuroPerspective features our comprehensive annual review of the Alzheimer's space, including a review of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets. In particular, for 2018 there is an expanded assessment of neuro-immunology as it pertains to Alzheimer's, including infection models of AD and tactics for modulating microglial activity. The
- [Autism and Mid-2018 Reviews](https://www.niresearch.com/autism-and-mid-2018-reviews/) - NI Research has released the July/August 2018 issue of NeuroPerspective. Its two review sections provide a mid-year review of the neurotherapeutics sector, including succinct summaries for over 80 companies in the neuro-space, and a comprehensive review of Autism. At midyear 2018, the neuro space has been impressively resilient in terms of partnering and funding, with
- [Addiction and Anxiety Reviewed](https://www.niresearch.com/addiction-and-anxiety-reviewed/) - The May/June 2018 issue of NeuroPerspective takes NP into a world of internal contradictions, in an issue that features reviews of Addiction and Anxiety. Addiction, in view of the American 'Opioid Epidemic', receives enormous press coverage in the US, but a relatively paltry slice of the federal funding pie, and a pathetically infinitesimal portion of pharma's R&D
- [Depression and PTSD Reviewed](https://www.niresearch.com/depression-and-ptsd-reviewed/) - The March/April 2018 issue of NeuroPerspective has been released, featuring in-depth reviews of Depression and PTSD. Depression represents a patient population whose treatment falls far short of the bucolic illustrations suggested by DTC advertising for the current crop of pharmacotherapies. The majority of patients do not find adequate relief from their first trial, and 25% do not
- [CNS Overview Issue For 2017-18](https://www.niresearch.com/cns-overview-issue-released/) - The January/February issue of NeuroPerspective has been released, and as is the annual tradition, it reviews 2017 and previews 2018. Over 80 companies have capsule summaries of important events and anticipations, including Acorda, Adamas, Alkahest, AgeneBio, Allergan, AveXis, Biogen, Biohaven, Blackthorn, Denali, Genentech, JNJ, Lilly, Lundbeck, Marinus, Minerva, Neuren, Neurocrine Biosciences, Newron, Perception, Pfizer, Roche,
- [Parkinson's and ALS Reviewed](https://www.niresearch.com/parkinsons-and-als-reviewed/) - NI Research has released the November/December issue of NeuroPerspective, which features our comprehensive reviews for two major neurodegenerative disorders: Parkinson’s and ALS. These reviews include a consideration of the current thinking around pathophysiology and therapeutic targets, including the protein aggregates considered to be associated with these disorders: Alpha-synuclein, TDP-43, and c9orf72. Neuroinflammation, GBA as a
- [Alzheimer's and ADHD Reviewed](https://www.niresearch.com/alzheimers-and-adhd-reviewed/) - The September/October issue of NeuroPerspective features our annual, epic, and comprehensive review of the Alzheimer's space, including a review of the current thinking around pathophysiology and therapeutic targets:An updated assessment on the roles of amyloid, tau, neuroinflammation, and other targets is included. The subtitle for the review is 'Reset, Reboot,Recalibrate', because the traditional modus operandi
- [Mid-Year Overview and SCI Review Released](https://www.niresearch.com/mid-year-overview-and-sci-review-released/) - The July/August issue of NeuroPerspective features our midyear appraisal of the CNS therapeutics sector, including capsule reviews of more than 100 neuro-oriented companies. It also includes a comprehensive review of Spinal Cord Injury, for which a confluence of regenerative pharmacotherapy and sophisticated neurorehabilitation techniques appears poised to offer the prospect of significant functional improvement in
- [NeuroPerspective Reviews Schizophrenia and Insomnia](https://www.niresearch.com/696-2/) - The May/June issue of NeuroPerspective for 2017 has been released, offering detailed reviews of two therapeutic areas, as well as coverage and commentary regarding significant developments in the CNS therapeutics space. The first therapeutic sector review covers Schizophrenia, the most devastating of all the psychiatric disorders, one which reflects the awkward melding of multiple schizophreniform disorders with very
- [NeuroPerspective Reviews Huntington’s and Epilepsy](https://www.niresearch.com/neuroperspective-reviews-huntingtons-and-epilepsy/) - NeuroPerspective Reviews Huntington’s and Epilepsy The March/April issue of NeuroPerspective for 2017 has been released, offering detailed reviews of important, under-served therapeutic areas, as well as coverage and commentary regarding significant developments in the CNS therapeutics space. The first therapeutic sector review is on Huntington’s, which offers more mechanistic clarity than its neurodegenerative peers, though the route
- [2016-17 Overview Issue Released](https://www.niresearch.com/2016-17-overview-issue-released/) - The January/February issue of NeuroPerspective for 2017 has now been published. The issue is our Annual Overview of the neurotherapeutics sector, with capsule reviews for 110 CNS companies of all sizes, a review of deal and funding trends; Highlights and Lowlights from 2016; as well as an assessment of major events coming up this year. The review provides insightful, candid

## Pages

- [Excerpts 2025-2022](https://www.niresearch.com/excerpts-2014/) - 2025 From NP Summer 2023 Issue STROKE The tide may finally be turning for drug development in stroke, a relatively recent, and dramatic departure from what had been a nearly complete abdication of responsibility by the industry regarding this substantial, undertreated area. More than in any other area of neuroscience, this revival of interest tends,
- [Publications](https://www.niresearch.com/publications/) - NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; NeuroLicensing 2007-2024; and published the Private CNS Company Review 2003-2012.
- [About/Contact](https://www.niresearch.com/about-nircontact/) - The development of improved treatments for neurological and psychiatric disorders is the greatest challenge confronting contemporary medicine. Indeed, neurodegenerative disorders, epitomized by Alzheimers, pose an ummatched threat to modern health care systems and the economic well being of society as a whole. Since 1995, NI Research has been the leading resource for independent information and
- [NeuroPerspective](https://www.niresearch.com/publications/neuroperspective/) - NeuroPerspective is the quarterly journal that pioneered the coverage of cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer's, Parkinson's, stroke, brain injury, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and recognition for its 'no-holds-barred' evaluations. Three issues each year cover three therapeutic areas in depth, along
- [Visual Stimuli](https://www.niresearch.com/visual-stimuli/) - Both for NIR's publications and presentations at professional meetings and corporate symposia, we occasionally utilize imagery to make a point in an unorthodox fashion. The intent is to provoke thought, though some of these images may be provocative in other ways. The goal is not snarkiness for its own sake: With the challenges that confront the
- [Unorthodox PowerPoints](https://www.niresearch.com/unorthodox-visual-commentary-excerpts/) - For NIR's publications, presentations at professional meetings, and talks at corporate symposia, we try to offer commentary that utilizes imagery to make the point in novel, creative, and entertaining fashion. The intent is to provoke thought, though some of these images may be provocative in other ways. The goal is not snarkiness for its own
- [Second Opinion Consulting](https://www.niresearch.com/second-opinion-consulting/) - Second Opinion Inlicensing opportunities Partnering strategies and targets Strategic portfolio planning NI Research began providing consultation services in 2001. We complete 4-6 projects annually, each project receives our full attention, and no one tracks the CNS space more closely than NIR. Some recent consultation projects have included: Collaborated with a multinational major pharmaceutical company
- [Panache ](https://www.niresearch.com/panache/) - In 2012, Elan Pharmaceuticals sent out a press release regarding their change in plan regarding CEO transitioning. As a masterpiece of indirectness, we chose to provide a satirical section-by-section 'translation', which was included at our annual presentation at ISCDD 2012, thinly disguised as referring to 'Panache Pharmaceuticals'. At that time, the silent film 'The Artist'
- [CNS Trend Data](https://www.niresearch.com/cns-trend-data/) - These slides provide a visual representation of the shift of R&D emphases 2009-13. Presented originally at CNS Summit 2013

## Categories

- [NeuroPerspective capsules](https://www.niresearch.com/category/neuroperspective-capsules/)

## Tags

- [neurotherapeutics](https://www.niresearch.com/tag/neurotherapeutics/)
- [Allergan](https://www.niresearch.com/tag/allergan/)
- [Alzheimer's](https://www.niresearch.com/tag/alzheimers/)
- [Epilepsy](https://www.niresearch.com/tag/epilepsy/)
- [Otsuka](https://www.niresearch.com/tag/otsuka/)
- [schizophrenia](https://www.niresearch.com/tag/schizophrenia/)
- [ALS](https://www.niresearch.com/tag/als/)
- [Marinus](https://www.niresearch.com/tag/marinus/)
- [Axovant](https://www.niresearch.com/tag/axovant/)
- [SAGE](https://www.niresearch.com/tag/sage/)
- [Merck](https://www.niresearch.com/tag/merck/)
- [Lilly](https://www.niresearch.com/tag/lilly/)
- [Novartis](https://www.niresearch.com/tag/novartis/)
- [Biogen](https://www.niresearch.com/tag/biogen/)
- [Depression](https://www.niresearch.com/tag/depression/)
- [autism](https://www.niresearch.com/tag/autism/)
- [Alkermes](https://www.niresearch.com/tag/alkermes/)
- [ketamine](https://www.niresearch.com/tag/ketamine/)
- [TBI](https://www.niresearch.com/tag/tbi/)
- [stroke](https://www.niresearch.com/tag/stroke/)
- [Neuren](https://www.niresearch.com/tag/neuren/)
- [aducanumab](https://www.niresearch.com/tag/aducanumab/)
- [amyloid](https://www.niresearch.com/tag/amyloid/)
- [tau](https://www.niresearch.com/tag/tau/)
- [MS](https://www.niresearch.com/tag/ms/)
- [Roche](https://www.niresearch.com/tag/roche/)
- [Centrexion](https://www.niresearch.com/tag/centrexion/)
- [Intra-Cellular](https://www.niresearch.com/tag/intra-cellular/)
- [PTSD](https://www.niresearch.com/tag/ptsd/)
- [SAGE Therapeutics](https://www.niresearch.com/tag/sage-therapeutics/)
- [Blackthorn](https://www.niresearch.com/tag/blackthorn/)
- [Rodin](https://www.niresearch.com/tag/rodin/)
- [SpringWorks](https://www.niresearch.com/tag/springworks/)
- [AbbVie](https://www.niresearch.com/tag/abbvie/)
- [Voyager](https://www.niresearch.com/tag/voyager/)
- [Denali](https://www.niresearch.com/tag/denali/)
- [Takeda](https://www.niresearch.com/tag/takeda/)
- [Wave Life Sciences](https://www.niresearch.com/tag/wave-life-sciences/)
- [Addiction](https://www.niresearch.com/tag/addiction/)
- [Anxiety](https://www.niresearch.com/tag/anxiety/)
- [opioid](https://www.niresearch.com/tag/opioid/)
- [Bionomics](https://www.niresearch.com/tag/bionomics/)
- [Addex](https://www.niresearch.com/tag/addex/)
- [Opiant](https://www.niresearch.com/tag/opiant/)
- [Indivior](https://www.niresearch.com/tag/indivior/)
- [Idorsia](https://www.niresearch.com/tag/idorsia/)
- [NeuroPerspective](https://www.niresearch.com/tag/neuroperspective/)
- [AveXis](https://www.niresearch.com/tag/avexis/)
- [Frontotemporal](https://www.niresearch.com/tag/frontotemporal/)
- [FTD](https://www.niresearch.com/tag/ftd/)
- [Alector](https://www.niresearch.com/tag/alector/)
- [Cortexyme](https://www.niresearch.com/tag/cortexyme/)
- [Rodin Therapeutics](https://www.niresearch.com/tag/rodin-therapeutics/)
- [Parkinson's](https://www.niresearch.com/tag/parkinsons/)
- [Zulresso](https://www.niresearch.com/tag/zulresso/)
- [Spravato](https://www.niresearch.com/tag/spravato/)
- [Cerevel](https://www.niresearch.com/tag/cerevel/)
- [Axsome](https://www.niresearch.com/tag/axsome/)
- [Huntington's](https://www.niresearch.com/tag/huntingtons/)
- [Compass Pathways](https://www.niresearch.com/tag/compass-pathways/)
- [ATAI](https://www.niresearch.com/tag/atai/)
- [Frontotemporal Dementia](https://www.niresearch.com/tag/frontotemporal-dementia/)
- [Prevail Therapeutics](https://www.niresearch.com/tag/prevail-therapeutics/)
- [Fragile X](https://www.niresearch.com/tag/fragile-x/)
- [Rett](https://www.niresearch.com/tag/rett/)
- [Libra](https://www.niresearch.com/tag/libra/)
- [Psychedelics](https://www.niresearch.com/tag/psychedelics/)
- [psilocybin](https://www.niresearch.com/tag/psilocybin/)
- [LSD](https://www.niresearch.com/tag/lsd/)
- [5-MeO-DMT](https://www.niresearch.com/tag/5-meo-dmt/)
- [arketamine](https://www.niresearch.com/tag/arketamine/)
- [MDMA](https://www.niresearch.com/tag/mdma/)
- [DMT](https://www.niresearch.com/tag/dmt/)
- [MAPS.org](https://www.niresearch.com/tag/maps-org/)
- [Multiple Sclerosis](https://www.niresearch.com/tag/multiple-sclerosis/)
- [Karuna](https://www.niresearch.com/tag/karuna/)
- [Autobahn](https://www.niresearch.com/tag/autobahn/)
- [Aduhelm](https://www.niresearch.com/tag/aduhelm/)
- [Longboard Pharma](https://www.niresearch.com/tag/longboard-pharma/)
- [Eisai](https://www.niresearch.com/tag/eisai/)
- [Cassava](https://www.niresearch.com/tag/cassava/)
- [Annovis](https://www.niresearch.com/tag/annovis/)
- [UniQure](https://www.niresearch.com/tag/uniqure/)
- [Parkinson's ALS](https://www.niresearch.com/tag/parkinsons-als/)
- [QurAlis](https://www.niresearch.com/tag/quralis/)
- [Prilenia](https://www.niresearch.com/tag/prilenia/)
- [Neumora](https://www.niresearch.com/tag/neumora/)
- [Neurvati](https://www.niresearch.com/tag/neurvati/)
- [Compass](https://www.niresearch.com/tag/compass/)
- [MindMed](https://www.niresearch.com/tag/mindmed/)
- [GH Research](https://www.niresearch.com/tag/gh-research/)
- [Gilgamesh](https://www.niresearch.com/tag/gilgamesh/)
- [Cybin](https://www.niresearch.com/tag/cybin/)
- [Xenon](https://www.niresearch.com/tag/xenon/)
- [Engrail](https://www.niresearch.com/tag/engrail/)
- [Praxis](https://www.niresearch.com/tag/praxis/)
- [Acadia](https://www.niresearch.com/tag/acadia/)
- [Alzheimer's](https://www.niresearch.com/tag/alzheimers-2/)
- [Amylyx](https://www.niresearch.com/tag/amylyx/)
- [lecanemab](https://www.niresearch.com/tag/lecanemab/)
- [Neurocrine](https://www.niresearch.com/tag/neurocrine/)
- [Parkinsons](https://www.niresearch.com/tag/parkinsons-2/)
- [Delix](https://www.niresearch.com/tag/delix/)
- [Small Pharma](https://www.niresearch.com/tag/small-pharma/)
- [Lusaris](https://www.niresearch.com/tag/lusaris/)
- [ADHD](https://www.niresearch.com/tag/adhd/)
- [Leqembi](https://www.niresearch.com/tag/leqembi/)
- [Anavex](https://www.niresearch.com/tag/anavex/)
- [Bayer AG](https://www.niresearch.com/tag/bayer-ag/)
- [BMS](https://www.niresearch.com/tag/bms/)
- [Longboard](https://www.niresearch.com/tag/longboard/)
- [Janssen/JNJ](https://www.niresearch.com/tag/janssen-jnj/)
- [Lundbeck](https://www.niresearch.com/tag/lundbeck/)
- [Maplight](https://www.niresearch.com/tag/maplight/)
- [Noema](https://www.niresearch.com/tag/noema/)
- [NoNO](https://www.niresearch.com/tag/nono/)
- [Ovid](https://www.niresearch.com/tag/ovid/)
- [Prothena](https://www.niresearch.com/tag/prothena/)
- [Reviva](https://www.niresearch.com/tag/reviva/)
- [Sosei Heptares](https://www.niresearch.com/tag/sosei-heptares/)
- [Transposon](https://www.niresearch.com/tag/transposon/)
- [UCB](https://www.niresearch.com/tag/ucb/)
- [Lykos](https://www.niresearch.com/tag/lykos/)
- [Dravet](https://www.niresearch.com/tag/dravet/)
- [Stoke](https://www.niresearch.com/tag/stoke/)
- [Vesper Bio](https://www.niresearch.com/tag/vesper-bio/)
- [Arkuda](https://www.niresearch.com/tag/arkuda/)
- [CIAS](https://www.niresearch.com/tag/cias/)
- [muscarinic](https://www.niresearch.com/tag/muscarinic/)
- [Kynexis](https://www.niresearch.com/tag/kynexis/)
- [ibogaine](https://www.niresearch.com/tag/ibogaine/)
- [Narcolepsy](https://www.niresearch.com/tag/narcolepsy/)
- [Reunion](https://www.niresearch.com/tag/reunion/)
- [Orexin](https://www.niresearch.com/tag/orexin/)
- [Harmony](https://www.niresearch.com/tag/harmony/)
- [AC Immune](https://www.niresearch.com/tag/ac-immune/)
- [Acumen](https://www.niresearch.com/tag/acumen/)
- [Actinogen](https://www.niresearch.com/tag/actinogen/)
- [Aspen](https://www.niresearch.com/tag/aspen/)
- [AtaiBeckley](https://www.niresearch.com/tag/ataibeckley/)
- [Alzamend](https://www.niresearch.com/tag/alzamend/)
- [Alto](https://www.niresearch.com/tag/alto/)
- [Biohaven](https://www.niresearch.com/tag/biohaven/)
- [BioArctic](https://www.niresearch.com/tag/bioarctic/)
- [Cybin/Helus](https://www.niresearch.com/tag/cybin-helus/)
- [Boehringer Ingelheim](https://www.niresearch.com/tag/boehringer-ingelheim/)
- [GSK](https://www.niresearch.com/tag/gsk/)
- [JNJ](https://www.niresearch.com/tag/jnj/)
- [Muna](https://www.niresearch.com/tag/muna/)
- [Myrobalan](https://www.niresearch.com/tag/myrobalan/)
- [Oryzon](https://www.niresearch.com/tag/oryzon/)
- [ProMIS](https://www.niresearch.com/tag/promis/)
- [Resilient](https://www.niresearch.com/tag/resilient/)
- [Rapport](https://www.niresearch.com/tag/rapport/)
- [Syremis](https://www.niresearch.com/tag/syremis/)
- [Sanofi](https://www.niresearch.com/tag/sanofi/)
- [Syndeio](https://www.niresearch.com/tag/syndeio/)
- [Seaport](https://www.niresearch.com/tag/seaport/)
- [Vesper](https://www.niresearch.com/tag/vesper/)
- [Definium](https://www.niresearch.com/tag/definium/)
- [Synchronicity](https://www.niresearch.com/tag/synchronicity/)
- [Neurona](https://www.niresearch.com/tag/neurona/)
- [Migraine](https://www.niresearch.com/tag/migraine/)
- [Atai Beckley](https://www.niresearch.com/tag/atai-beckley/)
- [Otsuka/Transcend](https://www.niresearch.com/tag/otsuka-transcend/)
- [Enveric](https://www.niresearch.com/tag/enveric/)
- [Equulus](https://www.niresearch.com/tag/equulus/)
- [Helus](https://www.niresearch.com/tag/helus/)
- [CaamTech](https://www.niresearch.com/tag/caamtech/)
- [Psilera](https://www.niresearch.com/tag/psilera/)
- [Skyhawk](https://www.niresearch.com/tag/skyhawk/)
- [Pfizer](https://www.niresearch.com/tag/pfizer/)